Stockscreener 앱 받기
2.85
5.00%
-0.15
시간 외 거래:
2.98
0.13
+4.56%
Eledon Pharmaceuticals Inc 주식(ELDN)의 최신 뉴스
Eledon Pharmaceuticals Reports Positive 2025 Results for Tegoprubart in Transplant Trials and Receives FDA Orphan Drug Designation - Minichart
Eledon Pharmaceuticals, Inc. 2026 Annual Report: Business Overview, Risk Factors, and Strategic Focus on Immunology and Tegoprubart Development 29 - Minichart
Eledon Pharmaceuticals (NASDAQ:ELDN) Announces Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
ELEDON PHARMACEUTICALS ($ELDN) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
Eledon Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results - The Manila Times
Eledon Pharmaceuticals 2025 net loss widens on higher R&D costs - TradingView
After islet transplants, 10 Eledon-treated diabetes patients went off insulin - Stock Titan
Eledon (NASDAQ: ELDN) 2025 results show higher R&D spend and cash - Stock Titan
Tegoprubart data and new orphan status headline Eledon (NASDAQ: ELDN) 2025 update - Stock Titan
Eledon Pharmaceuticals options imply 11.7% move in share price post-earnings - TipRanks
ELDN PE Ratio & Valuation, Is ELDN Overvalued - Intellectia AI
Eledon reports insulin independence in islet transplant trial By Investing.com - Investing.com Australia
Leerink Maintains Outperform on ELDN (Eledon Pharmaceuticals) March 16, 2026 - Meyka
Eledon Pharmaceuticals (ELDN) Presents Promising Diabetes Trial Results - GuruFocus
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego - GuruFocus
Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative - Seeking Alpha
Leerink Partners reiterates Outperform on Eledon stock at $5 By Investing.com - Investing.com Canada
Eledon announces updated data from investigator-initiated islet transplant trial of tegoprubart in patients with type 1 diabetes at UChicago Medicine - marketscreener.com
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine - Bitget
Eledon reports insulin independence in islet transplant trial - Investing.com
Eledon Pharmaceuticals Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Experimental transplant drug lets 10 diabetes patients stop insulin - Stock Titan
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Eledon Pharmaceuticals (ELDN) to Release Quarterly Earnings on Thursday - MarketBeat
Eledon Pharmaceuticals at Leerink Conference: Strategic Insights on Transplantation By Investing.com - Investing.com Canada
ELDN: Tegoprubart advances with strong safety data, phase 3 plans, and cash runway into Q2 2025 - TradingView
NewcelX partners with Eledon on type 1 diabetes therapy By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire
Eledon's Tegoprubart Gets FDA's Orphan Drug Designation In Liver Transplantation; Stock Up - RTTNews
Eledon Pharma wins FDA orphan status for lead asset (ELDN) - Seeking Alpha
Eledon Pharmaceuticals (ELDN) Gains FDA Orphan Drug Status for T - GuruFocus
FDA gives rare-disease status to drug aiming to protect liver transplants - Stock Titan
NewcelX and Eledon partner for NCEL-101 programme - Yahoo Finance
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation - Bitget
Newcelx partners with Eledon to advance NCEL-101 - BioWorld MedTech
NewcelX, Eledon Partner to Advance a Potential Functional Cure for Type 1 Diabetes - Contract Pharma
Eledon Pharmaceuticals (ELDN) Enters Research Partnership to Com - GuruFocus
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - TradingView
NewcelX partners with Eledon on type 1 diabetes therapy - Investing.com UK
Eledon’s Transplant Drug Is Heading Toward A Phase 3 Moment - Finimize
ELDN SEC FilingsEledon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock - MSN
Jobs Data: Is Eledon Pharmaceuticals Inc. stock a top pick in earnings seasonLong Setup & Daily Technical Forecast Reports - Naître et grandir
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference - Sahm
Targets Report: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingJuly 2025 Institutional & Risk Controlled Swing Alerts - baoquankhu1.vn
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Aug Gainers: Whats Eledon Pharmaceuticals Incs historical returnBond Market & Daily Stock Trend Watchlist - baoquankhu1.vn
ELDN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Arkansas woman participates in clinical trial to cure type one diabetes - KARK
What makes Eledon Pharmaceuticals Inc. stock attractive todayGlobal Markets & High Accuracy Trade Signal Alerts - mfd.ru
Will Eledon Pharmaceuticals Inc. stock deliver shareholder valueWeekly Investment Summary & Long-Term Safe Investment Ideas - mfd.ru
What’s the beta of Eledon Pharmaceuticals Inc. stock2025 Year in Review & Consistent Growth Equity Picks - mfd.ru
Can Eledon Pharmaceuticals Inc. expand its profit marginsGap Down & Free High Return Stock Watch Alerts - mfd.ru
Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for “Tego” at Conference - MarketBeat
Eledon Pharmaceuticals at Guggenheim Summit: Tegoprubart’s Promising Path By Investing.com - Investing.com Canada
1.20%
0.06%
자본화:
|
볼륨(24시간):